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Abstract
Background: Thrombotic and thromboembolic events are important causes of mortality and morbidity in patients with prosthetic 
heart valve. The aim of this study is to evaluate the factors that may contribute to prosthetic heart valve thrombosis. 
Methods: This was a cross-sectional study in Rajaie Heart Center on patients with prosthetic heart valve malfunction, within a 
year. According to the echocardiographic and fluoroscopic findings, the patients were divided into two groups (thrombosis and 
non-thrombosis groups). The patients’ demographic, clinical and laboratory data were recorded and analyzed with SPSS software. 
Results: A total of 142 patients participated in this study. Ninety-four patients (66.2%) were diagnosed with thrombosis.  There was 
a significant relationship between thrombosis and inadequate anti-coagulation (international normalized rati [INR] <2.5) (odds 
ratio [OR]: 4.15, 95% CI: 1.98-9.87, P = 0.003), history of infection (OR: 12.81, 95% CI: 3.52-19.02, P < 0.001), prothrombin 
time (PT) check interval (OR: 2.38, 95% CI: 1.63-8.47, P = 0.019), atrial fibrillation (AF) rhythm (OR: 3.96, 95% CI: 1.75-8.09, P 
= 0.019), and plasma fibrinogen level (OR: 6.90, 95% CI: 2.58-14.69). 
Conclusion: Based on this study, inadequate anti-coagulation, AF rhythm, recent infection and plasma fibrinogen level were 
the factors most contributing to prosthetic valve thrombosis. As there were many cases of thrombosis in patients with history of 
infection, this factor can be considered for risk assessment in prosthetic valve.
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An average of 350 000 heart valves are replaced worldwide 
every year.1 The main objective of valve replacement 
is to expand life expectancy and improve life quality in 
patients who have significant symptoms.2 One of the 
important steps in treatment of these patients is sufficient 
administration of anticoagulants to prevent thrombus 
formation on the valve.3 The incidence of prosthetic heart 
valve thrombosis depends on the type of the prosthetic 
valve. In mechanical valves, the risk of thrombosis 
is higher compared to biological valves. There is an 
incidence rate of thrombosis of approximately 0.1% to 
5.7% in mechanical heart valves and 0.03% in biological 
heart valves, reported every year. Also, it is reported that 
thrombosis occurs by a rate  between 0.1 to 6.0% for each 
year of patient’s age, in the mitral and the aortic valves and 
up to 20% in the tricuspid valve.4 Diagnostic techniques 
including echocardiography, fluoroscopy, and therapeutic 
measures involving re-surgery, thrombolytic therapy, 
or anti-coagulant treatments  impose significant costs 
on individuals and the whole community.5,6 Prosthetic 
Valve Thrombosis (PVT) results in valve malfunction, 
thromboembolic events, the clot serving as a nest for viral 
or bacterial growth, etc.7 This study aims to assess the risk 
factors and incidence of prosthetic valve thrombosis in 
patients with prosthetic valve malfunction.
Materials and Methods
Study Design and Participants
This was a cross-sectional study in Rajaie Heart Centre 
on patients with prosthetic heart valve malfunction. 
Depending on the purpose and type (census) of the study, 
all patients (referred from other hospitals, emergency 
admittance and routine visits) with valve malfunction 
(symptomatic or asymptomatic changes in the prosthetic 
valve’s hemodynamic status on echocardiographic 
assessment, including stenosis and regurgitation) from 
April 2015 to April 2016 were included in the study. 
The criteria for excluding patients were: 1) missing data 
obtained by laboratory tests or interview, and 2) the 
patient not consenting to the study.
In case of clinical suspicion for prosthetic valve 
thrombosis, transthoracic echocardiography was performed 
in advance. Based on the leaflet mobility and gradient, 
hemodynamic status, and identification of thrombus, 
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the absence of contraindications. The considered signs 
of thrombosis on echocardiography were restriction of 
leaflet mobility or observing echogenic thrombotic mass 
on the leaflet or valve ring. If thrombosis was diagnosed, 
fluoroscopy was performed to confirm the restriction of 
the related leaflet movement.8
Variables
The patients’ demographic data, in addition to medical 
and drug history, were obtained through interviews. 
The interviewer was blinded to the other data of the 
patients. Then, a blood sample was collected aseptically by 
antecubital puncture, followed by a urine test. Laboratory 
measurements included the international normalized 
ratio (INR), C-reactive protein (CRP), erythrocyte 
sedimentation rate (ESR), plasma fibrinogen level and 
proteinuria. Researchers who collected either the interview 
or laboratory data were blinded to the other data.
Statistical Analysis
The collected data were analyzed using the IBM SPSS 
Statistics software (version 16.0, SPSS, Chicago, Illinois). 
Chi-square test was used to compare qualitative variables. 
Quantitative variables were compared using Student’s 
t test. Significance differences were shown with odds 
ratio (95% CI) computed using chi-square test. Logistic 
regression was used to assess the relationship between 
the variables and PVT and determining the confounder 
effects. P values < 0.05 were considered significant. 
Results
Demographic Data and Medical History
A total of 154 eligible patients participated in the study. 
Twelve patients were excluded due to lack of co-operation 
or missing data. Finally, data from 142 patients were 
analyzed. Ninety-four patients (66.2%) were diagnosed 
with thrombosis and 48 (33.8%) were without thrombosis 
(infective endocarditis, para-valvular leakage, valve 
deterioration). One hundred and two patients (71.8%) 
had dyspnea at the time of presentation which was the 
most prevalent symptom. Thirteen patients (9.2%) 
had palpitation, 13 (9.2%) had CVA (cerebrovascular 
accidents) and TIA (transient ischemic attack) and 1 
(0.7%) experienced syncope. None of the patients were 
addicted to drugs or alcohol but 19 (13.4%) used to smoke 
cigarettes. Ninety-four patients (66.2%) were females and 
48 (33.8%) were males with an average (mean ± SD) age 
of 49.8 ± 13.13 years.  Seventy-five patients (52.8%) had 
a history of an infectious disease other than endocarditis 
in the month preceding admission [69 (92%) in the 
thrombosis versus 6 (8%) in the non-thrombosis group]: 
among them, 54 (72%) had upper respiratory infection 
(OR: 19.320, 95% CI: 7.323–50.969). According to the 
history of prothrombin time (PT) check intervals, 57 
patients (60.7%) with thrombosis versus 3 (6.2%) without 
thrombosis had erratic PT check. In other words, the non-
thrombosis group had considerably regular PT check 
intervals (P<0.001) (Table 1). Logistic regression showed 
that history of recent infection and PT check interval were 
Table 1. Patients’ Demographic Characteristics and Medical History




Female 65 (69.1) 29 (60.4)
0.298 1.468 0.711 3.033
Male 29 (30.9) 19 (39.6)
PT check interval
<1-month 2 (2.1) 6 (12.5) <0.001 1.09 0.95 1.25
Monthly 35 (37.2) 39 (81.3) Base — —
Erratic 57 (60.7) 3 (6.2) 8.67 2.88 26.11
Recent infection
<0.001 19.320 7.323 50.969Yes 69 (73.4) 6 (12.5)
No 25 (26.6) 42 (87.5)
Aspirin(80) + warfarin
<0.001 0.256 0.121 0.540Yes 36 (38.3) 34 (70.8)
No 58 (61.7) 14 (29.2)
Season
0.811 — — —
Spring 19 (20.2) 14 (29.2)
Summer 17 (18.1) 13 (27.1)
Fall 23 (24.5) 8 (16.6)
Winter 35 (37.2) 13 (27.1)
Replaced valve number
0.004 — — —
1 57 (60.6) 39 (81.3)
2 36 (38.3) 9 (18.7)
3 1 (1.1) 0 (0.0)
PT, prothrombin time; OR, odds ratio; CI, confidence interval.
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the risk factors most contributing to thrombosis (OR: 
12.81, 95% CI: 3.52–19.02, P<0.001 and OR: 2.38, 95% 
CI: 1.63-8.47, P = 0.019, respectively) (Table 2).
Clinical Findings
One hundred and twenty patients (84.5%) had normal 
metallic sound and 22 (15.5%) had reduced metallic 
sound. All of the reduced sounds pertained to the 
thrombosis group and the difference was significant (OR: 
1.66, 95% CI: 1.44–1.92, P<0.001).  Among patients 
with atrial fibrillation (AF), 52 (77.61%) were in the 
thrombosis group and 15 (22.39%) were in the non-
thrombosis group, indicating a significant difference (P = 
0.008) (Table 3). 
Also, a significant relationship was observed between AF 
rhythm and thrombosis (OR: 3.96, 95% CI: 1.75–8.09, P 
= 0.018). Additional information regarding the effects of 
these factors is illustrated in Table 2.
Laboratory Measurements
According to Table 4, the mean INR level was 1.8 in the 
first group and 2.3 in the second group. Thrombotic 
events were observed with significantly higher frequency 
in the patients with INR ≤ 2.5 (P<0.001). Analysis showed 
a direct relationship between the INR level of less than 
2.5 and thrombotic events (OR: 4.15, 95% CI: 1.98–
9.87, P = 0.003). The CRP level increased in 66 patients 
(46.5%), 55 of whom (83.33%) were in the thrombosis 
group. There was a significant difference between the 
two groups based on the CRP level (OR: 2.55, 95% CI: 
1.47–4.40, P<0.001). In the urine analysis, 37 patients 
(39.4%) had 1+ proteinuria and 7 patients (7.4%) had 
2+ proteinuria in the thrombosis group. In the non-
thrombosis group, no patient had 2+ proteinuria. There 
was a significant difference between the two groups based 
on the proteinuria level (P<0.001) (Table 4). According 
to Table 2, the effects of CRP and proteinuria were not 
significant in logistic regression. Although there was a 
significant difference between the two groups, they were 
considered as confounder factors (Table 2).
Discussion
Valvular heart disease is prevalent in developing countries. 
Surgical replacement is an advanced therapy for this 
disease, with optimal long-term results. One of the most 
important complications of valve replacement surgery 
Table 3. Patients’ Clinical and Imaging Findings




<0.001 1.66 1.44 1.92Decreased 22 (23.4) 0 (0.0)
Normal 72 (76.6) 48 (100)
Rhythm
0.008 1.77 1.12 2.79Sinus 42 (44.7) 33 (68.7)
AF 52 (55.3) 15 (31.3)
Fluoroscopy
<0.001 4.17 1.92 9.03Limited 49 (52.1) 6 (12.5)
Normal 45 (47.9) 42 (87.5)
LVEF
<35% 15 (15.9) 5 (10.4) 1.44 0.68 3.02
36%-50% 69 (73.4) 36 (75) 0.44 1.04 0.89 1.22
>50% 10 (10.6) 7 (14.6) Base — —
AF, atrial fibrillation; LVEF, left ventricular ejection fraction; OR, odds ratio; CI, confidence interval.
Table 2. Relationship Between Risk Factors and Thrombosis in Logistic Regression Analysis
Risk Factors P value OR
CI (95%)
Lower Upper
PT Check Interval 0.019 2.38 1.63 8.47
Recent infection <0.001 12.81 3.52 19.02
Concurrent use of aspirin and warfarin 0.138 0.211 0.027 1.65
Replaced valve number 0.282 2.47 0.292 5.51
CRP 0.100 2.11 0.656 4.56
Proteinuria 0.180 0.16 0.011 2.32
Plasma fibrinogen 0.006 6.90 2.58 14.69
Fluoroscopy 0.264 2.05 0.295 3.54
AF rhythm 0.018 3.96 1.75 8.09
INR level 0.003 4.15 1.98 9.87
PT, prothrombin time; CRP, C-reactive protein; AF, atrial fibrillation; INR, international normalized ratio; OR, odds ratio; CI, confidence interval.
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is dysfunction due to valve thrombosis which can lead 
to thromboembolic events and fatal stroke.4 According 
to Table 4, inadequate anti-coagulation at the time of 
admission had a strong relationship with thrombosis. 
Similarly, as mentioned in other studies, the cause of 
thrombosis in prosthetic valves is often due to insufficient 
anticoagulation, which is directly related to the patients’ 
culture and their awareness regarding correct use of 
anticoagulant drugs.4,9 The most common symptom 
at the time of admission was dyspnea, and later with 
other findings such as palpitation, CVA, TIA, decreased 
prosthetic valve sounds and syncope. These findings are 
consistent with another study conducted by Bonou et al.10 
In this study, the highest rate of thrombosis observed was 
in winter in the months of January and February (Table 
1). Pham et al11 reported that PVT has a higher prevalence 
during winter compared to other seasons. It seems that this 
caused by the change in plasma fibrinogen levels in different 
seasons. In winter, plasma fibrinogen levels increase. Also, 
the increase in plasma viscosity in this season may be the 
cause for an increase in thrombosis. Our study also found 
a significant relationship between plasma fibrinogen 
levels and thrombosis which increased the incidence of 
thrombosis in those with higher plasma fibrinogen levels. 
This also confirms all above.12 In this study, AF rhythm on 
ECG had a direct and significant relationship with valve 
thrombosis. Dürrleman et al.13 reported that AF rhythm 
was observed in 45% of patients with PVT. Furthermore, 
Cáceres-Lóriga et al14 reported that this rhythm was present 
in 56% of patients with PVT and there was a significant 
relation between AF and thrombosis, which is consistent 
with our study. The results show a significant relationship 
between history of infection, particularly upper respiratory 
infection in the month preceding admission, and PVT. 
Since none of the patients with previous infections, 
especially upper respiratory tract infection, were diagnosed 
with endocarditis, it can be argued that the presence 
of upper respiratory tract infections without direct 
involvement of cardiac tissue, could be an independent 
factor in development of thrombotic events in prosthetic 
valves. We did not find any study addressing this issue in 
the databases. In this study, the CRP level was considered 
as a confounder factor for PVT, but Gürsoy et al15 reported 
that the increased CRP level contributed to the prosthetic 
mitral valve thrombosis. A possible reason why this factor 
was considered a confounding factor in this study is that 
CRP is an acute phase reactant and can change quickly in 
conditions other than valve dysfunction. We also found 
proteinuria level as a confounding factor.
One of the limitations of our study was the presence 
of infection before the patients’ admission as a subjective 
item. We were not able to confirm the presence of infection 
with para-clinical tests, and we could not differentiate 
the bacterial or the viral nature of the infection. Another 
limitation was that our study was conducted in a single 
clinical heart center. Consequently, the results may not 
have enough power or validity to be generalized. Also, in 
this study, we did not evaluate the effect of the time lapse 
between valve surgery and the dysfunction which could be 
an important factor; this needs to be considered in future 
studies.
In conclusion, based on the results of our study, it may be 
Table 4. Laboratory Measurements




<1.5 34 (36.2%) 5 (10.4%) 3.32 1.51 7.31
1.5-2.5 49 (52.1%) 26 (54.2%) <0.001 2.91 1.19 7.12
>2.5 11 (11.7%) 17 (35.4%) Base — —
Mean 1.8 2.35 — — —
CRP
Normal 39 (41.5%) 37 (77.1%)
< 0.001 2.55 1.47 4.40
Increased 55 (58.5%) 11 (22.9%)
ESR
0.698 1.19 0.49 2.90
Normal 80 (85.1%) 42 (87.5%)
Increased 14 (14.9%) 6 (12.5%)
Proteinuria
Normal 50 (53.2%) 41 (85.4%) Base — —
+1 37 (39.4%) 7 (14.6%) < 0.001 2.91 1.41 6.03
+2 7 (7.4%) 0 (0.0%) 1.54 1.15 3.14
Plasma fibrinogen
< 0.001 24.51 3.48 172.19
Normal 46 (48.9%) 47 (97.9%)
Increased 48 (51.1%) 1 (2.1%)
INR, international normalized ratio; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; OR, odds ratio; CI, confidence interval.
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concluded that inadequate anti-coagulation, AF rhythm, 
recent infection and plasma fibrinogen level are the factors 
most contributing to prosthetic valve thrombosis. Due to 
the high rates of thrombosis in patients with history of 
recent infection, this factor can be considered as a factor 
in prosthetic valve risk assessment, requiring further 
investigations in larger populations.
Authors’ Contribution
FNB: made total concept, designing the study and manuscript 
review. HAB: definition of intellectual content and design the study. 
SG: searching the literatures, manuscript preparation, definition 
of intellectual content and data curation. HA: designing the study, 
performing clinical section, data acquisition and manuscript 
editing. TR: data statictical analysis.
Conflict of Interest Disclosures
Hereby the authors declare no conflict of interest.
Ethical Statement
The study was conducted in accordance with the principles of the 
declaration of Helsinki and approved by the ethic committee of Iran 





We would like to express our special thanks to all of patients for 
their kind cooperation in this study. Moreover we thank Mr. Naser 
Reshadmanesh for his noteworthy consultations regarding the 
statistical analysis. The abstract of this study has been presented 
(oral presentation) at the 23rd European Heart Disease and Failure 
Congress, on February 19-21, 2018, in Paris, France.
References 
1. Zilla P, Brink J, Human P, Bezuidenhout D. Prosthetic heart 
valves: catering for the few. Biomaterials. 2008;29(4):385-
406. doi: 10.1016/j.biomaterials.2007.09.033.
2. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, 
Fleisher LA, et al. AHA/ACC focused update of the 2014 AHA/
ACC guideline for the management of patients with valvular 
heart disease: a report of the American College of Cardiology/
American Heart Association Task Force on Clinical Practice 
Guidelines. J Am Coll Cardiol. 2017;70(2):252-89. doi: 
10.1016/j.jacc.2017.03.011.
3. Iung B, Rodés-Cabau J. The optimal management of anti-
thrombotic therapy after valve replacement: certainties and 
uncertainties. Eur Heart J. 2014;35(42):2942-9. doi: 10.1093/
eurheartj/ehu365.
4. Dangas GD, Weitz JI, Giustino G, Makkar R, Mehran 
R. Prosthetic heart valve thrombosis. J Am Coll Cardiol. 
2016;68(24):2670-89. doi: 10.1016/j.jacc.2016.09.958.
5. Krishnan S. Prosthetic heart valve thrombosis: diagnosis 
and newer thrombolytic regimes. J Pract Cardiovasc Sci. 
2016;2(1):7-12. doi: 10.4103/2395-5414.182993.
6. Biteker M, Altun I, Basaran O, Dogan V, Yildirim B, Ergun G. 
Treatment of prosthetic valve thrombosis: current evidence 
and future directions. J Clin Med Res. 2015;7(12):932-6. doi: 
10.14740/jocmr2392w.
7. Roudaut R, Serri K, Lafitte S. Thrombosis of prosthetic heart 
valves: diagnosis and therapeutic considerations. Heart. 
2007;93(1):137-42. doi: 10.1136/hrt.2005.071183.
8. Otto CM. The practice of clinical echocardiography. 5th ed. 
USA: Elsevier Health Sciences; 2017: 455-480.
9. Salamon J, Munoz-Mendoza J, Leibelt JJ, Taub CC. Mechanical 
valve obstruction: Review of diagnostic and treatment 
strategies. World J Cardiol. 2015;7(12):875-81. doi: 10.4330/
wjc.v7.i12.875.
10. Bonou M, Lampropoulos K, Barbetseas J. Prosthetic heart 
valve obstruction: thrombolysis or surgical treatment? 
Eur Heart J Acute Cardiovasc Care. 2012;1(2):122-7. doi: 
10.1177/2048872612451169.
11. Pham N, Zaitoun H, Mohammed TL, DeLaPena-Almaguer E, 
Martinez F, Novaro GM, et al. Complications of aortic valve 
surgery: manifestations at CT and MR imaging. Radiographics. 
2012;32(7):1873-92. doi: 10.1148/rg.327115735.
12. Piper C, Hering D, Horstkotte D. Prosthetic valve 
thrombosis: predisposition and diagnosis. Eur Heart J 
Suppl. 2001;3(suppl_Q):Q16-Q21. doi: 10.1016/S1520-
765X(01)90037-9.
13. Dürrleman N, Pellerin M, Bouchard D, Hébert Y, Cartier R, 
Perrault LP, et al. Prosthetic valve thrombosis: twenty-year 
experience at the Montreal Heart Institute. J Thorac Cardiovasc 
Surg. 2004;127(5):1388-92. doi: 10.1016/j.jtcvs.2003.12.013.
14. Cáceres-Lóriga FM, Pérez-López H, Santos-Gracia J, Morlans-
Hernandez K. Prosthetic heart valve thrombosis: pathogenesis, 
diagnosis and management. Int J Cardiol. 2006;110(1):1-6. 
doi: 10.1016/j.ijcard.2005.06.051.
15. Gürsoy OM, Karakoyun S, Kalçık M, Gökdeniz T, Yesin 
M, Gündüz S, et al. Usefulness of novel hematologic 
inflammatory parameters to predict prosthetic mitral valve 
thrombosis. Am J Cardiol. 2014;113(5):860-4. doi: 10.1016/j.
amjcard.2013.11.029.
                    © 2020 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.
org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
